Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EPS (Weighted Average and Diluted) (2017 - 2025)

Viking Therapeutics' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at -$1.39 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 334.37% year-over-year to -$1.39; the TTM value through Dec 2025 reached -$3.19, down 215.84%, while the annual FY2025 figure was -$3.19, 215.84% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.39 at Viking Therapeutics, down from -$0.81 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.16 in Q4 2021 and bottomed at -$1.39 in Q4 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.24 (2023), against an average of -$0.35.
  • The largest annual shift saw EPS (Weighted Average and Diluted) rose 13.64% in 2023 before it plummeted 334.37% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.16 in 2021, then crashed by 62.5% to -$0.26 in 2022, then increased by 7.69% to -$0.24 in 2023, then crashed by 33.33% to -$0.32 in 2024, then tumbled by 334.37% to -$1.39 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's EPS (Weighted Average and Diluted) are -$1.39 (Q4 2025), -$0.81 (Q3 2025), and -$0.58 (Q2 2025).